In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s499209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Wenyu Du und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Hebei Medical University, Shijiazhuang, 050017, People's Republic of China. Hauptthemen laut MEDLINE: Pyridones, Pyrazoles, Pyridines, Piperazines. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School, Hebei Medical University, Shijiazhuang, 050017, People's Republic of China.
- Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China.
ORCID-Profile: Zhi Wang
Zitieren
APA
Du, W., Liu, Z., Li, Y., Wang, Z., & Dong, Z. (2025). In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s499209
Vancouver
Du W, Liu Z, Li Y, Wang Z, Dong Z. In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s499209
BibTeX
@article{Du2025,
author = {Du, Wenyu and Liu, Zihan and Li, Ying and Wang, Zhi and Dong, Zhanjun},
title = {In vivo Pharmacokinetic Interactions Between Palbociclib and Rivaroxaban or Apixaban: Implications for Increased Drug Exposure and Dose Adjustments},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s499209}
}
EUVIMED